4.82
price up icon2.77%   0.13
pre-market  プレマーケット:  4.79   -0.03   -0.62%
loading

Y Mabs Therapeutics Inc (YMAB) 最新ニュース

pulisher
Apr 20, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Apr 20, 2025
pulisher
Apr 20, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Update - Defense World

Apr 20, 2025
pulisher
Apr 14, 2025

ExodusPoint Capital Management LP Buys New Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - The AM Reporter

Apr 14, 2025
pulisher
Apr 13, 2025

KLP Kapitalforvaltning AS Acquires New Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Prudential Financial Inc. Lowers Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity (YMAB) - Seeking Alpha

Apr 11, 2025
pulisher
Apr 09, 2025

Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation - openPR.com

Apr 09, 2025
pulisher
Apr 07, 2025

YMAB LAWSUIT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Fraud Class Action Filed - ACCESS Newswire

Apr 07, 2025
pulisher
Apr 07, 2025

Pediatric Neuroblastoma Treatment Market Size in 7MM - openPR.com

Apr 07, 2025
pulisher
Apr 02, 2025

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 12% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st

Apr 02, 2025
pulisher
Apr 02, 2025

Refractory Metastatic Melanoma Clinical and Non-Clinical - openPR.com

Apr 02, 2025
pulisher
Mar 29, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stake Boosted by Charles Schwab Investment Management Inc. - Defense World

Mar 29, 2025
pulisher
Mar 27, 2025

(YMAB) Long Term Investment Analysis - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

Top Premarket Decliners - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Mar 26, 2025
pulisher
Mar 23, 2025

HC Wainwright Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their Views - Benzinga

Mar 21, 2025
pulisher
Mar 17, 2025

Learn to Evaluate (YMAB) using the Charts - news.stocktradersdaily.com

Mar 17, 2025
pulisher
Mar 13, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Mar 13, 2025
pulisher
Mar 12, 2025

Y-mabs therapeutics CBO Gad Thomas sells $56,536 in stock - Investing.com India

Mar 12, 2025
pulisher
Mar 11, 2025

Y-mabs therapeutics CEO Michael Rossi sells $20,368 in stock By Investing.com - Investing.com South Africa

Mar 11, 2025
pulisher
Mar 11, 2025

Y-mabs therapeutics CBO Gad Thomas sells $56,536 in stock By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Y-mabs therapeutics CEO Michael Rossi sells $20,368 in stock - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Y-mAbs Therapeutics Executives Sell Shares - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates - MSN

Mar 11, 2025
pulisher
Mar 11, 2025

YMAB Q1 EPS Estimate Boosted by Brookline Capital Management - MarketBeat

Mar 11, 2025
pulisher
Mar 09, 2025

Bearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimates - Yahoo

Mar 09, 2025
pulisher
Mar 08, 2025

FY2025 EPS Estimates for YMAB Reduced by Cantor Fitzgerald - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Wedbush Reduces Earnings Estimates for Y-mAbs Therapeutics - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Brookline Capital Management Predicts YMAB Q1 Earnings - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025 - Baystreet.ca

Mar 07, 2025
pulisher
Mar 07, 2025

Y-mAbs Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St

Mar 07, 2025
pulisher
Mar 07, 2025

Bank of America Lowers Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00 - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Morgan Stanley Issues Pessimistic Forecast for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Truist Financial Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World

Mar 07, 2025
pulisher
Mar 05, 2025

Forecasting The Future: 4 Analyst Projections For Y-mAbs Therapeutics - Benzinga

Mar 05, 2025
pulisher
Mar 05, 2025

Y-mAbs Therapeutics price target lowered to $12 from $14 at BofA - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 05, 2025
pulisher
Mar 05, 2025

Oppenheimer Adjusts Y-mAbs Therapeutics Price Target to $21 From $23, Maintains Outperform Rating - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Truist Cuts Price Target on Y-mAbs Therapeutics to $18 From $21, Keeps Buy Rating -March 05, 2025 at 06:27 am EST - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Call Highlights: Strategic Realignment and ... By GuruFocus - Investing.com Canada

Mar 05, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics Reports 2024 Financial Results - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics’ Earnings Call Highlights Mixed Results - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics inks equity deal up to $35M - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics Inc Enters Equity Distribution Agreement With Oppenheimer -March 04, 2025 at 04:32 pm EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics inks equity deal up to $35M By Investing.com - Investing.com UK

Mar 04, 2025
pulisher
Mar 04, 2025

SEC Form 424B5 filed by Y-mAbs Therapeutics Inc. - Quantisnow

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs stock price target cut to $19 at Cantor Fitzgerald - Investing.com UK

Mar 04, 2025
pulisher
Mar 04, 2025

Wedbush Cuts Price Target on Y-mAbs Therapeutics to $21 From $23, Keeps Outperform Rating - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 79% loss from investing in the stock five years ago - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs announces publication of Phase 2 interim results on naxitamab - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Therapeutics Reports Fourth Quarter 2024 Financial Results - TradingView

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Reports Fourth Quarter 2024 Financial Results -March 04, 2025 at 07:06 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments - The Manila Times

Mar 04, 2025
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
大文字化:     |  ボリューム (24 時間):